tiprankstipranks
Keymed Biosciences, Inc. (HK:2162)
HKEX:2162
Hong Kong Market
Holding HK:2162?
Track your performance easily

Keymed Biosciences, Inc. (2162) Stock Price & Analysis

0 Followers

2162 Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

2.28%95.15%
Insiders
― Other Institutional Investors
95.15% Public Companies and
Individual Investors

2162 FAQ

What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$26.60 and its highest was HK$47.50 in the past 12 months.
    What is Keymed Biosciences, Inc.’s market cap?
    Currently, no data Available
    When is Keymed Biosciences, Inc.’s upcoming earnings report date?
    Keymed Biosciences, Inc.’s upcoming earnings report date is Apr 01, 2025 which is in 82 days.
      How were Keymed Biosciences, Inc.’s earnings last quarter?
      Keymed Biosciences, Inc. released its earnings results on Aug 27, 2024. The company reported -HK$1.368 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$1.368.
        Is Keymed Biosciences, Inc. overvalued?
        According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Keymed Biosciences, Inc. pay dividends?
          Keymed Biosciences, Inc. does not currently pay dividends.
          What is Keymed Biosciences, Inc.’s EPS estimate?
          Keymed Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Keymed Biosciences, Inc. have?
          Keymed Biosciences, Inc. has 279,735,570 shares outstanding.
            What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
            Keymed Biosciences, Inc. reported an EPS of -HK$1.368 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.313%.
              Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
              Currently, no hedge funds are holding shares in HK:2162
              ---

              Keymed Biosciences, Inc. Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Keymed Biosciences, Inc.

              Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
              ---

              2162 Stock 12 Month Forecast

              Average Price Target

              HK$60.47
              ▲(115.96% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"HK$28","61":"HK$61","36.25":"HK$36.3","44.5":"HK$44.5","52.75":"HK$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$60.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$60.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,36.25,44.5,52.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,31.502307692307692,33.95461538461539,36.40692307692308,38.85923076923077,41.31153846153846,43.76384615384615,46.216153846153844,48.66846153846154,51.12076923076923,53.573076923076925,56.02538461538462,58.47769230769231,{"y":60.93,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,31.466923076923077,33.88384615384616,36.300769230769234,38.71769230769231,41.13461538461539,43.55153846153846,45.96846153846154,48.385384615384616,50.80230769230769,53.21923076923077,55.636153846153846,58.05307692307693,{"y":60.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,31.430769230769233,33.81153846153846,36.19230769230769,38.573076923076925,40.95384615384616,43.33461538461539,45.715384615384615,48.09615384615385,50.47692307692308,52.857692307692304,55.238461538461536,57.61923076923077,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.8,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.3,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.45,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.95,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.2,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.2,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.5,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.7,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.65,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.4,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.65,"date":1735257600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.05,"date":1735862400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Akeso, Inc.
              CanSino Biologics, Inc. Class H
              Times Neighborhood Holdings Ltd.
              Everest Medicines Ltd.

              Best Analysts Covering 2162

              1 Year
              1 Year Success Rate
              0/1 ratings generated profit
              0%
              1 Year Average Return
              -3.40%
              reiterated a buy rating 10 days ago
              Copying Wangbin Zhou's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -3.40% per trade.
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis